Histone Variant H2A.Z Can Serve as a New Target for Breast Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|17|28|3155-3161

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.17, Iss.28, 2010-09, pp. : 3155-3161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histone Deacetylation: An Attractive Target for Cancer Therapy?

By Al-Janadi Anas   Chandana Sreenivasa R.   Conley Barbara A.  

Drugs in R&D, Vol. 9, Iss. 6, 2008-01 ,pp. : 369-383

Adis International

Access to resources Recommend Favorite

The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy

By  

Current Medicinal Chemistry, Vol. 15, Iss. 27, 2008-11 ,pp. : 2840-2849

Bentham Science Publishers

Access to resources Recommend Favorite

Target-based Anti-angiogenic Therapy in Breast Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 27, 2012-09 ,pp. : 4244-4257

Bentham Science Publishers

Access to resources Recommend Favorite

The NK-1 Receptor: A New Target in Cancer Therapy

By  

Current Drug Targets, Vol. 12, Iss. 6, 2011-06 ,pp. : 909-921

Bentham Science Publishers

Access to resources Recommend Favorite

The mu opioid receptor: A new target for cancer therapy?

By  

Cancer, Vol. 121, Iss. 16, 2015-08 ,pp. : 2681-2688

Blackwell Publishing

Access to resources Recommend Favorite